ModifiedOscar HealthPolicy N/A

Oral Cancer Screening and Testing

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage and reimbursement criteria for oral, oropharyngeal, HPV-related, salivary, molecular, biomarker, and other adjunctive tests used to screen for, detect, diagnose, or establish tumor status in oral and oropharyngeal cancer. It applies to providers and facilities submitting claims, subject to member benefits, state requirements, contracts, authorization, and medical-necessity requirements.

Policy Summary

PayerOscar Health

PolicyOral Cancer Screening and Testing

Policy CodePolicy N/A

Change TypeModified

Effective DateJan 1, 2027

Last ReviewSep 28, 2026

Next Review DateNot specified

Key ActionDocument the qualifying cancer diagnosis and the purpose of establishing HPV tumor status when submitting high-risk HPV mRNA expression testing.

SourceLink

POLICY UPDATE CHANGES

The Indications and/or Limitation of Coverage section was updated.

CPT codes 81599, 82397, 88341, and 88342 were removed from the Applicable CPT/HCPCS Procedure Codes section.

The evidence-based scientific references were updated.

60,480

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedOscar HealthPolicy N/A

Oral Cancer Screening and Testing

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerOscar Health

PolicyOral Cancer Screening and Testing

Policy CodePolicy N/A

Change TypeModified

Effective DateJan 1, 2027

Last ReviewSep 28, 2026

Next Review DateNot specified

Key ActionDocument the qualifying cancer diagnosis and the purpose of establishing HPV tumor status when submitting high-risk HPV mRNA expression testing.

SourceLink

POLICY UPDATE CHANGES

The Indications and/or Limitation of Coverage section was updated.

CPT codes 81599, 82397, 88341, and 88342 were removed from the Applicable CPT/HCPCS Procedure Codes section.

The evidence-based scientific references were updated.

60,480

Estimated U.S. diagnoses in 2026

13,150Estimated U.S. deaths in 2026

All newly diagnosed OPSCCCAP recommendation

Coverage Criteria

Covered HPV Tumor-Status Testing

Coverage is subject to the individual's benefit coverage at the time of the request. Covered when ALL of the following are met:

ALL of the following

The individual has oropharyngeal squamous cell carcinoma or metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.
Testing is performed to establish HPV tumor status.
Testing is for high-risk HPV using mRNA expression testing for HPV E6/E7.

Noncovered Screening and Diagnostic Tests

The following screening and diagnostic testing does not meet criteria for coverage:

ALL of the following

The testing is intended to screen for, detect, or diagnose oral cancer.
The testing is not high-risk HPV mRNA expression testing for HPV E6/E7 used to establish tumor status in an applicable individual.

Noninvasive tests designed to screen for, detect, or diagnose oral cancer, including the OmniPathology Oropharyngeal HPV PCR Test, DO NOT MEET CRITERIA.

To screen for, detect, or diagnose oral cancer, salivary biomarker testing, including testing for peptides, proteins, nucleic acids, or metabolites; genotyping of HPV, such as OraRisk® HPV; gene-expression profiling; panels that incorporate genetic risk factors with nongenetic biomarkers; and detection of HPV from an oropharyngeal swab DO NOT MEET CRITERIA.

The noncovered noninvasive and molecular oral cancer screening and diagnostic tests listed above do not meet criteria because there is a lack of available published scientific literature confirming that the tests are required and beneficial for the diagnosis and treatment of an individual's illness.

Applicable Procedure Codes

Applicable CPT/HCPCS Procedure CodesCPT

87624	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result
87625	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
87626	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types (eg, 16, 18, 31, 45, 51, 52) and high-risk pooled result(s)

Proprietary Testmixed

Proprietary test

Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68; Omnipathology Oropharyngeal HPV PCR Test; lab/manufacturer: OmniPathology Solutions, Medical Corporation

Provider Documentation and Billing Actions

Documentation Required

Accurate Service Documentation and Coding

Submit accurate documentation of the services performed and code claims appropriately according to applicable industry-standard coding and billing requirements.

Follow applicable Uniform Billing Editor, AMA/CPT, CPT Assistant, HCPCS, ICD-10-CM/PCS, NDC, DRG, CMS NCCI, CCI edit, and other CMS guidelines, as applicable.

Documentation Required

Support the HPV Tumor-Status Indication

Document the qualifying indication when testing is used to establish HPV tumor status in a patient with oropharyngeal squamous cell carcinoma or metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.

High-risk HPV mRNA expression testing for HPV E6/E7 meets criteria for these indications.

Documentation Required

Clinical Background

Oral cancer is malignancy arising in the oral cavity, including the area between the vermilion border of the lips, the junction of the hard and soft palates, and the posterior one-third of the tongue. Oral squamous cell carcinoma is the predominant type of oral cancer. HPV is associated with oropharyngeal and head and neck squamous cell carcinoma; however, the CDC states that no approved HPV test is available to find HPV in the mouth or throat.

Definitions and Abbreviations

Definition

Oral cancerCancer occurring in the oral cavity between the vermilion border of the lips and the junction of the hard and soft palates or the posterior one-third of the tongue.

Definition

HPVHuman papillomavirus.

Definition

HPV HRHuman papillomavirus high-risk.

Definition

OPC

Covered Clinical Indications

Establish HPV Tumor Status

High-risk HPV mRNA expression testing meets criteria to establish tumor status when the applicable disease indication is present.

Required indication and testing method

Applicable indication
- The individual has oropharyngeal squamous cell carcinoma.
- The individual has metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.
Testing uses high-risk HPV mRNA expression testing for HPV E6/E7 to establish HPV tumor status.High-risk HPV mRNA expression testing for HPV E6/E7

Newly Diagnosed Oropharyngeal Squamous Cell Carcinoma

Eligibility Requirements

For equivocal p16 immunostaining, defined as 50%-70% staining or extensive but weak staining, CAP recommends HPV-specific testing. HPV-specific testing is also recommended when p16 staining is discordant with morphology, for large multisite tumors overlapping the oropharynx, for non-tonsillar and non-base-of-tongue oropharyngeal sites, or when required by a clinical trial.

For squamous cell carcinoma of unknown primary, p16 and EBER testing are recommended; when p16 is positive, another specific HPV test should be performed to confirm HPV status.

Noncovered Services

The OmniPathology Oropharyngeal HPV PCR Test is not covered when used as a noninvasive screen for oral or oropharyngeal cancer. The following approaches also do not meet criteria for oral cancer screening, detection, or diagnosis: salivary biomarker testing, including peptides, proteins, nucleic acids, or metabolites; HPV genotyping, including OraRisk HPV; gene-expression profiling; panels incorporating genetic risk factors with nongenetic biomarkers; and detection of HPV from an oropharyngeal swab.

Policy Summary

PayerOscar Health

PolicyOral Cancer Screening and Testing

Policy CodePolicy N/A

Change TypeModified

Effective DateJan 1, 2027

Last ReviewSep 28, 2026

Next Review DateNot specified

Key ActionDocument the qualifying cancer diagnosis and the purpose of establishing HPV tumor status when submitting high-risk HPV mRNA expression testing.

SourceLink

On This Page

Follow Up OralCDx Results

All OralCDx atypical and positive results must be confirmed by incisional biopsy and histology to completely characterize the lesion. Persistent lesions require adequate follow-up evaluations even when the OralCDx result is negative.

Address persistent oral lesions with appropriate follow-up evaluation.

Denial Risk

Inaccurate Documentation or Coding May Result in Denial

Claims may be denied and/or payment may be recouped when documentation, coding, billing guidelines, or current reimbursement policy requirements are not followed.

Coverage does not guarantee reimbursement; applicable authorization, medical-necessity, benefit, and state-specific requirements still apply.

Billing Rule

Covered HPV Tumor-Status Indication

Testing to establish HPV tumor status is covered only for qualifying oropharyngeal squamous cell carcinoma or metastatic squamous cell carcinoma of unknown primary origin in a cervical lymph node.

The qualifying testing is high-risk HPV mRNA expression testing for HPV E6/E7.

Unsupported block type: denial_risk

Denial Risk

Excluded Oral Cancer Testing Approaches

The following approaches do not meet criteria for screening, detection, or diagnosis of oral cancer because published scientific literature does not establish that they are required and beneficial for diagnosis and treatment.

Salivary biomarker testing, including peptides, proteins, nucleic acids, or metabolites.
HPV genotyping, such as OraRisk® HPV.
Gene expression profiling.
Panels incorporating genetic risk factors with nongenetic biomarkers.
Detection of HPV from an oropharyngeal swab.

Oropharyngeal cancer.

Definition

SCCUPSquamous cell carcinoma of unknown primary.

Definition

mRNAMessenger ribonucleic acid.

Definition

IHCImmunohistochemistry.

Definition

COEConventional oral examination.

For newly diagnosed oropharyngeal squamous cell carcinoma, CAP strongly recommends high-risk HPV testing.

CAP recommendation

The individual has newly diagnosed oropharyngeal squamous cell carcinoma.
High-risk HPV testing is performed.All newly diagnosed OPSCC
Strong recommendation; evidence level high.
For an oropharyngeal tissue specimen, p16 immunohistochemistry is used as the surrogate marker for high-risk HPV.
CAP recommends surrogate-marker p16 immunohistochemistry for oropharyngeal tissue specimens; HPV-specific testing is recommended in specified scenarios such as equivocal p16 staining or discrepancy between p16 staining and morphology.

Sinonasal Squamous Cell Carcinoma

CAP conditionally recommends high-risk HPV testing for sinonasal squamous cell carcinoma.

CAP conditional recommendation

The individual has sinonasal squamous cell carcinoma.
High-risk HPV testing is performed.
Conditional recommendation; evidence level moderate.

Metastatic Squamous Cell Carcinoma of Unknown Primary in a Cervical Lymph Node

CAP strongly recommends high-risk HPV testing for metastatic squamous cell carcinoma of unknown primary in a cervical lymph node.

CAP strong recommendation

The individual has metastatic squamous cell carcinoma of unknown primary in a cervical lymph node.
High-risk HPV testing is performed.
Strong recommendation; evidence level high.

Level II and III Squamous Cell Carcinoma of Unknown Primary Nodes

For squamous cell carcinoma of unknown primary involving level II or III cervical nodes, ASCO recommends routine high-risk HPV testing and consideration of Epstein-Barr virus testing when the metastasis is HPV-negative.

ASCO recommendation

The individual has squamous cell carcinoma of unknown primary involving a level II or III cervical lymph node.
Routine high-risk HPV testing is performed.
ASCO recommends routine high-risk HPV testing.
When the metastasis is HPV-negative, Epstein-Barr virus testing is considered.
Consideration applies to HPV-negative metastases; it is not a prerequisite for high-risk HPV testing.